Great health tech dies in pilots
Fix your innovation friction
In the world of healthtech, we love to celebrate the breakthrough. We applaud the innovative algorithm, the groundbreaking wearable, or the diagnostic platform that promises to revolutionise patient outcomes. We hand out awards for technical brilliance.
But behind closed doors, there is a silent, growing frustration shared by investors, executives, and founders alike: the massive, seemingly unbridgeable gap between a brilliant technical solution and its actual adoption in healthcare systems.
For many healthtech and medtech companies, the initial excitement of funding eventually hits a brick wall. This is rarely due to a flawed product. Your algorithm is likely excellent. Your user interface is probably intuitive.
More often, the failure is one of translation. A highly skilled team spends eighteen months perfecting their code and running clinical trials, only to find that hospital buyers, procurement managers, and payers are speaking a completely different language. It is a language focused heavily on risk mitigation, existing workflows, and brutal budget cycles.
When that wall is hit, the company doesn’t just slow down. It risks stalling entirely.
The core problem is "Innovation Friction"
Healthcare is notoriously resistant to rapid change, and for good reason—human lives are at stake. However, this inherent and necessary caution creates a phenomenon we can call "Innovation Friction."
Startups and established medtech firms alike often arrive at the hospital door expecting to be welcomed simply because they are "innovative." They expect red carpets. Instead, they are met with a complex, highly defensive, risk-averse system that asks two very basic, unromantic questions:
"How does this make my current, difficult day easier?"
"Who is going to pay for this when our department budget is already in a deficit?"
Right now, countless companies are operating under the dangerous assumption that their clinical evidence is enough to drive sales. They expect the market to beat a path to their door because the data proves their product works.
Unfortunately, evidence of clinical efficacy is rarely the same as evidence of operational utility.
A health system’s medical director might entirely agree that your product works. But if adopting it requires them to reconfigure their entire nursing workflow, pull resources for a three-month IT integration, or navigate a labyrinthine twelve-month procurement process, the answer will almost always be "no."
They are not rejecting your technology. They are rejecting the friction required to implement it.
Why This Matters (And Why Executives Must Care Now)
If you are a strategy director, a market access leader, or an investor in the healthtech space, this isn't just a minor hurdle in your sales cycle. It is an existential risk to the business.
The Burn Rate Reality
Every month your commercial team spends trying to figure out "how to sell this thing" is a month of cash burn with no corresponding revenue. A typical healthtech startup might have 18 to 24 months of runway. A typical hospital procurement cycle, from first meeting to signed contract—, an take 12 to 18 months. If you do not have your go-to-market operational strategy locked in on day one, the math simply does not work. You will run out of money before they run out of bureaucracy.
The Trap of "Pilot Purgatory"
For investors, the primary concern is capital efficiency. If your portfolio companies are struggling to gain commercial traction, you are effectively watching your investment lose its potential ROI every single day they remain trapped in "pilot purgatory." This is the phase where a hospital agrees to a free or heavily discounted trial of your tech, but lacks the internal mechanisms, budget, or desire to convert that trial into an enterprise-wide contract. The startup gets a logo for their pitch deck, but no sustainable revenue.
Building the Wrong Product
For founders and product teams, the danger is becoming specialised in the wrong direction. Without a clear, unvarnished view of the healthcare buyer’s actual operational pain points, you risk building features that look fantastic on a slide deck but provide zero value in a chaotic, real-world clinical setting. You start dedicating engineering hours to solving problems that nobody in the hospital is actually losing sleep over.
The hard truth: The market does not care how hard you worked on your technology. It only cares how easily your technology solves its immediate problems.
The Three Fatal Flaws in Healthtech Go-To-Market Strategies
To fix the problem of market adoption, we first have to dissect why the standard approach fails. Most healthtech commercial strategies break down across three distinct flaws.
Flaw 1: Confusing the "User" with the "Buyer"
In healthtech, the person who uses your product is almost never the person who pays for it. Your medical device might be used by an orthopedic surgeon. The surgeon loves it. But the surgeon does not hold the purse strings.
The buyer is a committee made up of the Chief Financial Officer (CFO), the Chief Information Officer (CIO), procurement heads, and department leads. You can win the clinical champion (the surgeon), but if you cannot provide a compelling financial and operational case to the procurement committee, the deal dies. Many medtech firms fail because their entire pitch is tailored to the user, with nothing left for the buyer.
Flaw 2: Ignoring the "Switching Cost"
Even if your software saves a hospital money in the long run, adopting it costs them time, energy, and resources in the short term. This is the "switching cost."
If a new digital health platform saves a nurse 10 minutes per shift, but requires 15 hours of mandatory training and requires the IT department to spend four weeks integrating it with the Electronic Health Record (EHR) system, the hospital is going to pass. The perceived switching cost outweighs the eventual benefit.
Flaw 3: The Language Barrier
Listen to a healthtech founder pitch, and you will hear words like disruptive, AI-driven, neural networks, predictive analytics, and optimisation.
Listen to a hospital administrator talk, and you will hear words like reimbursement codes, staff shortages, bed flow, waitlist backlogs, and compliance.
When healthtech companies fail to translate their technical features into the operational language of the hospital, the buyer tunes out.
Moving Beyond the "Build and Hope" Strategy
The solution to overcoming innovation friction isn't necessarily securing a larger funding round to weather the storm. It also isn't hiring a massive, expensive enterprise sales team to hammer away at closed hospital doors.
Often, the solution is deep, structural, strategic alignment.
To bridge the adoption gap, medtech and healthtech companies must fundamentally shift their focus. You must move away from Product Readiness and obsess over System Readiness. (Here's another article arguing for Product-System-Fit)
This means understanding that the "go-live" moment is not the finish line. It is barely the starting line. It is the beginning of a complex operational integration. Succeeding requires a Go-To-Market strategy that explicitly maps how your product will survive inside the hospital's ecosystem.
1. Map the Operational Reality
Before you try to sell, you must understand the environment you are selling into. How does the hospital currently manage the problem you are trying to solve? Who is manually typing in the data? What forms are they using? If you insert your technology into that workflow, what happens to the person immediately before and immediately after your intervention? If you cannot map the workflow, you cannot sell the solution.
2. Reduce Cognitive Load
Hospitals are currently facing unprecedented staffing shortages and rampant burnout. If your tool adds even one extra click to a clinician's day, it is a liability. Your pitch must explicitly demonstrate how your product reduces cognitive and operational load on staff. You are not selling software; you are selling time.
3. Align with Urgent Strategic Priorities
Hospitals do not buy "nice-to-have" innovations. They buy solutions to their most acute, bleeding-neck problems. Right now, those problems are waitlist management, acute admission reductions, elective recovery, and staff retention. If you can articulate your product's value in the context of these specific, urgent metrics, you stop being perceived as an "innovation experiment" and start being treated as an "operational partner."
Redefining your Commercial Approach From a Vendor to Partner
The companies that succeed in the current healthcare landscape are rarely the ones with the absolute most advanced, cutting-edge technology. They are the ones that have mastered the art of commercial and operational integration.
They don't just know their own product; they know the hospital's procurement thresholds. They know whether they need to position their solution as an operational expenditure (OpEx) or a capital expenditure (CapEx) to get approval faster. They know how to arm their clinical champions with the exact financial documentation the CFO needs to see to authorise the purchase.
They stop trying to force the door open with brute sales force, and instead, they start building the exact key that fits the lock.
To achieve this, leadership teams within healthtech firms need to ask themselves hard, uncomfortable questions:
Are we selling a clinical benefit, but ignoring the operational cost of implementing it?
Have we mapped out every single stakeholder required to say "yes" to our product, or are we just talking to the people who like our tech?
Is our commercial strategy designed to navigate hospital bureaucracy, or are we hoping the bureaucracy will change for us?
If you don't have definitive, confident answers to these questions, your go-to-market strategy has a blind spot that will eventually cost you money, time, and market share.
The Missing Link
Many startups and mid-market medtech firms simply lack the internal bandwidth or the institutional experience to navigate this complex environment. And there is no shame in that. Your team is comprised of brilliant technical experts, software engineers, and clinical researchers. They are not hospital procurement experts, and they shouldn't have to be.
However, ignoring the problem will not make it go away. Healthtech teams need outside, objective pressure-testing. They need someone who can look at their business model, tear it down, and rebuild it against the harsh realities of hospital purchasing behavior.
It is time for the industry to stop viewing market adoption as a marketing problem. It is not a branding issue. It is an operational problem. And until that operational problem is solved, even the most transformative, life-saving healthtech will remain locked outside the hospital doors.
Buoyancy Health Strategy works with healthtech portfolios to bridge the critical gap between technical innovation and healthcare market adoption. He helps executive teams accelerate revenue and escape "pilot purgatory" while protecting investor capital, doing so by translating complex technical solutions into clear, operational strategies that hospitals actually say "yes" to.
Buoyancy Health Strategy
Steady. Strategic. Scalable Healthcare Growth
© 2025 Buoyancy Health Strategy Ltd. All rights reserved.